Skip links

Glutathione: why protect its cellular concentrations in anti-aging?

Andrea Tognelli, Pharmacist – Florence

The key points

– In January 2024 an article in the International Journal of Molecular Sciences (1) explored the functions of mitochondrial glutathione (mGSH) in oxidation-reductive systems, and in other important biomechanisms connected with the activities of mitochondria and human cells.

These functions can be compromised by lowering cellular concentrations of mGSH and total GSH.

A decline due to advancing age and the action of endogenous and exogenous agents in the organism. This trend is comparable to the progressive loss of other constituents of cellular antioxidant systems: enzymatic, e.g.: superoxide dismutase (SOD), catalase (CAT), and non-enzymatic, e.g.: coenzyme Q10, vitamins C and E.

– Low concentrations of mGSH and cellular GSH, together with mitochondrial oxidative stress, are associated with aging and the pathogenesis of many age-related diseases. In these processes, the presence of inflammation is also found, which contributes to supporting a vicious circle with oxidative processes and alterations of the mitochondria (1, 2).

– It is essential to maintain or recover adequate concentrations of mGSH and an optimal GSH/GSSG (glutathione disulfide) ratio in cells to protect and reactivate mitochondrial and cellular functions (1, 2).

– Experimental and clinical studies confirm the value of specific antioxidant treatments aimed at mitochondria (3, 4), and in particular aimed at resolving mitochondrial dysfunction. An alteration that is at the center of the various biomechanisms of aging, which are closely related to each other (5, 6).

– The involvement of mitochondria and mitochondrial dysfunction in aging and related diseases is the subject of continuous research, as demonstrated by the Nature – Signal Transduction and Target Therapy article of May 2024, which analyzes ways to prevent and/or reactivate mitochondria and the contribution of targeted treatments on these cellular organelles (7).

– Intervention on GSH levels finds a specific meaning, not as a sole treatment, but in synergy with additional molecules aimed at reducing oxidative stress, mitochondrial dysfunction and inflammation, to effectively slow down systemic aging processes and cutaneous (3, 4, 8).

– Even in the most recent literature, the use of GSH precursors, such as N-acetylcysteine ​​(NAC), is among those most studied and used, also due to their high tolerability, both for clinical uses and in anti-aging treatments and related disorders (1, 2).

– NAC is one of the main components of Mitofast bit.ly/3VUlGkS the orosoluble supplement studied by scientific research Mitochon srl https://www.mitochon.it/.

In Mitofast NAC is associated with resveratrol, coenzyme Q10, N-acetylglucosamine, folic acid, vitamin C.

They are molecules equipped with specific and well-documented mechanisms of action, which converge on preserving and reactivating the functions of mitochondria and cells, as necessary interventions to slow down the processes of systemic and skin aging (9, 10, 11, 12, 13 , 14).

GSH: general characteristics and functions

Reduced glutathione (GSH) is a powerful antioxidant fundamental for the cellular oxidation-reduction system, in fact, it helps to remove reactive oxygen species (ROS), such as superoxide and hydrogen peroxide, which can damage DNA, l ‘RNA and proteins lead to cell death. GSH is the main non-protein thiol molecule present in animal cells, where in the cytoplasm it is synthesized from cysteine, glutamic acid and glycine, through biochemical reactions dependent on adenosine triumphate (ATP) (15).

The intracellular redox balance is maintained through a cycle:

– glutathione peroxidase oxidizes GSH to glutathione disulfide  (GSSG)

– GSSG is then reduced by glutathione reductase and returned to GSH.

Maintaining the balance of the GSH/GSSG ratio is essential to control the growth, development and oxidative defense of cells. Therefore their ratio is an indicator of cellular health, where GSSG must mostly be reconverted into GSH, the reduced form that counteracts ROS and performs other important tasks (1). Total GSH concentrations are physiologically low in plasma (1–6 μM), but are much higher in cells (1–10 mM), including erythrocytes and other blood components (16, 17, 18, 19). GSH plays a very important role in numerous metabolic pathways, including: DNA and protein synthesis; transport of amino acids, enzymatic activations, functioning of the immune system, removal of free radicals, co-factor in detoxification mediated by cytochrome P450 enzymes, transfer of amino acids across cell membranes, detoxification from xenobiotics (e.g. drugs, pollutants), maintenance of the hydrogen sulfide groups of proteins, of the DNA of the mitochondria and of their functioning (20, 21, 22).

Fig 1 Glutathione

National Center for Biotechnology Information (2024). PubChem Compound Summary for CID 124886, Glutathione. Retrieved May 19, 2024 from https://pubchem.ncbi.nlm.nih.gov/compound/Glutathione.

Mitochondrial GSH

In addition to producing energy (ATP), mitochondria are also the main producers of ROS, generated largely by the electron transport chain. ROS within certain levels are involved in various molecular signaling systems, therefore necessary for mitochondrial and cellular homeostasis. To maintain this balance, mitochondria require constant protection from excess ROS, which is exerted by cellular antioxidant systems (1, 2, 23, 24).

Among these, GSH, and mGSH in particular, plays a key role in the mitochondria, where it is transported from the cell cytoplasm via carrier proteins, carries out antioxidant and detoxifying activity from external substances, stabilizes mitochondrial DNA and is involved in other mechanisms. , e.g.: oxidative phosphorylation (OXPHOS) for the production of adenosine triumphate (ATP) and the biosynthesis of iron – sulfur proteins.

Mitochondrial mGSH represents 10-15% of cellular GSH, which in the cytoplasm under physiological conditions is present in 85% in the reduced form. While in mitochondria under physiological conditions, GSH is in higher concentrations (about 99%) due to the reduced volume of the mitochondrial matrix, and GSSG is less than 1% (1).

In the case of an excess of ROS, there is a lowering of physiological concentrations of mGSH, consequently basal mitochondrial respiration and ATP production are significantly reduced (1).

GSH deficiency is considered a hallmark of impaired mitochondrial activities (19, 20, 21).

In fact, when the excess of ROS is no longer adequately neutralized, a state of mitochondrial dysfunction is established, which is a prelude to programmed cell death. This process includes apoptosis, autophagy, necroptosis and ferroptosis which can occur simultaneously or sequentially, in addition to their direct interaction (1, 2).

As anticipated, in addition to GSH, the antioxidant action is also carried out by other molecules physiologically present in cells and mitochondria, through the enzymatic and non-enzymatic antioxidant system. In particular, stimulating the synthesis of GSH helps to prevent the loss of mitochondrial membrane potential and inhibit apoptosis (1).

GSH at the skin level

Antioxidants such as GSH, vitamin C and E, coenzyme Q10, CAT and SOD are concentrated in the deeper layers of the stratum corneum of the epidermis, compared to the dermis. This distribution would derive from the need to ensure protection to the epidermal stem cells present in the dermal-epidermal junction, where the greatest production of ROS also occurs (8).

Environmental factors such as  UV rays and air pollutants stimulate the production of ROS, which leads to greater consumption of cellular GSH to neutralize them (25).

In addition to the increase in ROS, with advancing age the capacity for synthesis and recycling of GSH decreases, followed by the alteration of the GSH/GSSG ratio. Therefore, antioxidant and detoxifying defenses decrease at the skin level, conditions that accelerate the onset of the signs of aging, a phenomenon that is also found in the hair follicles (8, 25).

GSH at a systemic level

At a systemic level, the reduced availability of cellular GSH, as well as other cellular antioxidants, is also associated with many pathological conditions, characterized by increased oxidative stress, inflammatory processes and mitochondrial dysfunction (16, 26, 26, 28).

In fact, a study conducted for 6 years in over 2,900 subjects aged > 60 years confirmed the association of low GSH levels with a high rate of multi-morbidity (29).

Low levels of GSH and a low GSH/GSSG ratio are present in cardiometabolic diseases (2), in chronic respiratory diseases (e.g. asthma, COPD), in liver diseases, in smokers (1, 2), in degenerative eye diseases (2 , 30).

The onset of Alzheimer’s and Parkinson’s diseases is also partly associated with the decline of GSH (1).

In these neurodegenerative diseases, low GSH levels contribute to exacerbating oxidative stress and generate neuroinflammation (31, 32).

A systematic review further confirmed the decline in GSH levels throughout adult life, highlighting the increase in oxidative stress affecting brain structures, and also identified the different brain localizations of GSH levels and vulnerability to oxidative damage/ inflammatory. These important acquisitions are the subject of further studies to understand the dynamics of onset of neurodegenerative diseases (27). For example, in May 2024 the journal NeuroImage published a study on 276 healthy subjects between 20-70 years old, where it is anticipated that variations in GSH levels could predict the fate of visuospatial memory (33).

The evaluation of GSH levels is proposed as a further parameter to estimate biological age (34).

Reduced levels of GSH have been observed in inflammatory states caused by microbial (1) and viral infections (35, 36).

Regarding GSH levels, there are also gender differences, with higher levels in women than in men (24).

A recent acquisition, a study published in April 2024 by The American Journal of Clinical Nutrition identified low protein intake in the elderly as one of the causes of reduced GSH synthesis (37).

How to maintain / restore adequate intracellular levels of GSH and the GSH/GSSG ratio

As anticipated, counteracting the decline of GSH represents an important objective in treatments against the molecular, cellular and tissue mechanisms that determine systemic and skin aging.

Oral use

The oral administration of GSH presents some critical issues:

– low bioavailability, because in the gastro-intestinal tract it is broken down into the amino acids that constitute it;

– reduced penetration into cells.

To solve the problem of GSH degradation, new oral formulations have been studied, which have currently collected limited clinical evidence in humans, despite proving promising (2, 22, 38, 39, 40).

Other routes of administration of GSH have been adopted: the parenteral route for clinical use, in addition to the intra-nasal and sublingual route, which would be problematic or ineffective (2).

Oral use of GSH precursors

The use of GSH precursors arises from the observation that the availability of cysteine ​​is the limiting factor for the synthesis of GSH (2).

The most studied and used cysteine ​​precursor in clinic is N-acetylcysteine ​​(NAC), which is rapidly absorbed orally in the small intestine and reaches peak plasma concentration between 30 minutes and one hour, and is then subjected to hepatic metabolism (2, 21).

Fig 2 N-acetylcysteine

National Center for Biotechnology Information (2024). PubChem Compound Summary for CID 12035, Acetylcysteine. Retrieved May 19, 2024 from https://pubchem.ncbi.nlm.nih.gov/compound/Acetylcysteine.

Unlike GSH (16, 17, 41), NAC can cross the phospholipid membrane of cells, inside them it is deacetylated by N-deacetylase, releasing cysteine ​​which, combining with glycine and glutamic acid, generates GSH (1, 35 ).

The ROS removal activity is supported not only by the increase in cellular GSH concentrations, but also by a direct antioxidant activity of NAC.

In fact, this molecule performs various functions, among these (42, 43):

– is involved in mechanisms capable of reducing and splitting the disulfide bonds responsible for protein aggregation (e.g. mucolytic function).

– increases the endogenous production of H2S which at certain cellular concentrations has demonstrated cytoprotective effects. H2S release mechanisms contribute to inhibiting apoptosis, improve mitochondrial bioenergetics and perform antioxidant functions (44).

– the release of cysteine ​​by NAC produces further sulfur derivatives to which important protective effects on cells are attributed, in addition to those deriving from the synthesis of GSH (44).

– has anti-inflammatory capabilities by reducing the production of cytokines.

For many years, NAC has been used by infusion as an antidote in paracetamol overdose, in addition to oral administration as a mucolytic. There is extensive scientific documentation on the clinical use of NAC in the cardiovascular, pneumological, dermatological and neuro-psychiatric fields (42, 45, 46).

From an antiaging perspective, it is interesting to know the results of some studies carried out with NAC:

– helps to counteract the oxidative stress caused by UV rays, the cause of photo-aging, and intervenes in the cutaneous inflammatory mechanisms present in aging and in various skin disorders (47, 48, 49). Furthermore, in May 2024 in an article in the journal Biomedicine & Pharmacotherapy dedicated to gero-protective interventions against skin aging, NAC is cited for increasing the expression of sirtuins, present in the body as a class of proteins with enzymatic activity that mediate the mechanisms of aging (50).

– potential senolytic and senomorphic activities were detected (Note 1), as well as interesting benefits on some parameters related to obesity, e.g.: fasting blood sugar, insulin resistance, indicators of inflammation, such as C-reactive protein and cytokines ( 51).

– the activities carried out by NAC would also allow it to act on endothelial dysfunction and the pathogenetic mechanisms of atherosclerosis (52, 53), and in those of neurodegenerative diseases (54, 55, 56). The contribution of NAC has also been found in association with other molecules (57), with beneficial effects on muscular and cognitive performance (58), and on the molecular and cellular mechanisms of the hallmarks of aging, among which mitochondrial dysfunction has a central role (5, 6, 59, 60).

Topical use

GSH has a reduced penetration into the horny layer of the skin, therefore particular formulations based on new pharmaceutical technologies have been studied for topical use (61, 62).

The topical use of GSH and its precursors demonstrates specific antioxidant activities, and in particular against pollutants (63, 64).

The Mitochon srl https://www.mitochon.it/ dermocosmetic line uses GSH in association with other molecules with an antioxidant and bioactive action: resveratrol, coenzyme Q10, folic acid, N-acetylglucosamine, retinyl palmitate, tocopherol, fatty acids and ceramides . These molecules are formulated with P.AS.S.® (Permeable AntioxidantS System) pharmaceutical technology to make them more bioavailable and stable.

Parenteral use

The intramuscular and intravenous administration of GSH has specific clinical indications and, pending specific studies, its application in anti-aging treatments and physical recovery is expected to be interesting.

At the moment only in some Asian countries, where intravenous administration at high doses of GSH for skin whitening is widespread, the health authorities have drawn attention to the possible side effects and the absence of studies on this type of use off-lable (22, 65, 66). Problems that have also been disclosed by some international websites dedicated to health, which have nevertheless highlighted the possible advantages (22, 67, 68, 69, 70, 71, 72, 73).

Conclusions

– The most recent research highlights the importance of maintaining adequate levels of cellular GSH to counteract the mechanisms of aging and the onset of age-related diseases.

– The use of GSH precursors, such as N-acetylcysteine ​​(NAC) orally, proves to be an effective and safe choice, with new findings on geroprotective activities.

– NAC in synergy with the mechanisms of action of other molecules contributes to maintaining and re-establishing the homeostasis of mitochondria and cells subjected to multiple exogenous and endogenous stresses on the organism.

Note 1 (74)

Senolytics: synthetic or natural molecules, for example contained in foods (e.g. polyphenols, vitamins) capable of eliminating senescent cells.

Senescent cells promote inflammatory and oxidative stress conditions at a systemic level, their number increases with age.

Senescent cells produce the secretory phenotype (senescence-associated secretory phenotype, SASP) which contributes to the onset of chronic systemic inflammation.

Senomorphic: molecules that reduce or suppress the secretory phenotype (anti-SASP)

Bibliography

1. Chen, T.-H.; Wang, H.-C.; Chang, C.-J.; Lee, S.-Y. Mitochondrial Glutathione in Cellular Redox Homeostasis and Disease Manifestation. Int. J. Mol. Sci. 2024, 25, 1314. https://doi.org/10.3390/ijms25021314

2. Giustarini, D.; Milzani, A.; Dalle-Donne, I.; Rossi, R. How to Increase Cellular Glutathione. Antioxidants 2023, 12, 1094. https://doi.org/10.3390/antiox12051094

3. Lee, Y.H.; Kuk, M.U.; So, M.K.; Song, E.S.; Lee, H.; Ahn, S.K.; Kwon, H.W.; Park, J.T.; Park, S.C. Targeting Mitochondrial Oxidative Stress as a Strategy to Treat Aging and Age-Related Diseases. Antioxidants 2023, 12, 934. https://doi.org/10.3390/antiox12040934

4. Protasoni, M.; Serrano, M. Targeting Mitochondria to Control Ageing and Senescence. Pharmaceutics 2023, 15, 352. https://doi.org/10.3390/pharmaceutics15020352 https://www.mdpi.com/1999-4923/15/2/352

5. Li Y, Berliocchi L, Li Z, Rasmussen LJ. Interactions between mitochondrial dysfunction and other hallmarks of aging: Paving a path toward interventions that promote healthy old age. Aging Cell. 2024 Jan;23(1):e13942. doi: 10.1111/acel.13942.

6. Lopez-Otin, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2023). Hallmarks of aging: An expanding universe. Cell, 186(2), 243–278. https://doi.org/10.1016/j.cell.2022.11.001

7. Zong Y, Li H, Liao P, Chen L, Pan Y, Zheng Y, Zhang C, Liu D, Zheng M, Gao J. Mitochondrial dysfunction: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024 May 15;9(1):124. doi: 10.1038/s41392-024-01839-8.

8. Papaccio, F.; D′Arino, A.; Caputo, S.; Bellei, B. Focus on the Contribution of Oxidative Stress in Skin Aging. Antioxidants 2022, 11, 1121. https://doi.org/10.3390/antiox11061121

9. Mini-Review N-acetilcisteina https://www.mitochon.it/n-acetilcisteina-nac-dalla-clinica-allanti-aging/

10. Mini-Review Acido Folico https://www.mitochon.it/acido-folico-dalla-clinica-allantiaging-attualita-2024/

11. Mini-Review Resveratrolo https://www.mitochon.it/resveratrolo-lintegrazione-nel-peri-e-post-menopausa-per-cute-e-molto-altro/

12. Mini-Review Coenzima Q10 https://www.mitochon.it/coenzima-q10-anti-aging-mitocondriale-per-la-pelle/

13. Mini-Review Vitamina C https://www.mitochon.it/vitamina-c-il-contributo-per-lanti-aging-cutaneo/

14. Mini-Review N-acetilglusosamina https://www.mitochon.it/n-acetilglucosamina-nag-per-il-trofismo-cutaneo/

15. Brodzka, S.; Baszyński, J.; Rektor, K.; Hołderna-Bona, K.; Stanek, E.; Kurhaluk, N.; Tkaczenko, H.; Malukiewicz, G.; Woźniak, A.; Kamiński, P. The Role of Glutathione in Age-Related Macular Degeneration (AMD). Int. J. Mol. Sci. 2024, 25, 4158. https://doi.org/10.3390/ijms25084158

16. Vázquez-Meza, H.; Vilchis-Landeros, M.M.; Vázquez-Carrada, M.; Uribe-Ramírez, D.; Matuz-Mares, D. Cellular Compartmentalization, Glutathione Transport and Its Relevance in Some Pathologies. Antioxidants 2023, 12, 834. https://doi.org/10.3390/antiox12040834

17. Ballatori N, Krance SM, Marchan R, Hammond CL. Plasma membrane glutathione transporters and their roles in cell physiology and pathophysiology. Mol Aspects Med. 2009 Feb-Apr;30(1-2):13-28. doi: 10.1016/j.mam.2008.08.004. 

18. Wróblewska, J.; Wróblewski, M.; Hołyńska-Iwan, I.; Modrzejewska, M.; Nuszkiewicz, J.; Wróblewska, W.; Woźniak, A. The Role of Glutathione in Selected Viral Diseases. Antioxidants 2023, 12, 1325. https://doi.org/10.3390/antiox12071325

19. Hakuna L, Doughan B, Escobedo JO, Strongin RM. A simple assay for glutathione in whole blood. Analyst. 2015 May 21;140(10):3339-42. doi: 10.1039/c5an00345h.

20. Sekhar RV. GlyNAC Supplementation Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Aging Hallmarks, Metabolic Defects, Muscle Strength, Cognitive Decline, and Body Composition: Implications for Healthy Aging. J Nutr. 2021 Dec 3;151(12):3606-3616. doi: 10.1093/jn/nxab309. 

21. Raghu G, Berk M, Campochiaro PA, Jaeschke H, Marenzi G, Richeldi L, Wen FQ, Nicoletti F, Calverley PMA. The Multifaceted Therapeutic Role of N-Acetylcysteine (NAC) in Disorders Characterized by Oxidative Stress. Curr Neuropharmacol. 2021;19(8):1202-1224. doi: 10.2174/1570159X19666201230144109.

22. Sharma DK, Sharma P. Augmented Glutathione Absorption from Oral Mucosa and its Effect on Skin Pigmentation: A Clinical Review. Clin Cosmet Investig Dermatol. 2022;15:1853-1862 https://doi.org/10.2147/CCID.S378470

23. von Bohlen und Halbach, O. Controlling glutathione entry into mitochondria: potential roles for SLC25A39 in health and (treatment of) disease. Sig Transduct Target Ther 7, 75 (2022). https://doi.org/10.1038/s41392-022-00928-w

24. Marí M, de Gregorio E, de Dios C, Roca-Agujetas V, Cucarull B, Tutusaus A, Morales A, Colell A. Mitochondrial Glutathione: Recent Insights and Role in Disease. Antioxidants (Basel). 2020 Sep 24;9(10):909. doi: 10.3390/antiox9100909

25. Cui X, Mi T, Xiao X, Zhang H, Dong Y, Huang N, et al. Topical glutathione amino acid precursors protect skin against environmental and oxidative stress. J Eur Acad Dermatol Venereol. 2024; 38(Suppl. 3): 3–11. https://doi.org/10.1111/jdv.19717

26. Ioannis Zalachoras, et Al. Therapeutic potential of glutathione-enhancers in stress-related psychopathologies, Neuroscience & Biobehavioral Reviews, Volume 114, 2020, Pages 134-155, https://doi.org/10.1016/j.neubiorev.2020.03.015.

27. Detcheverry F, Senthil S, Narayanan S, Badhwar A. Changes in levels of the antioxidant glutathione in brain and blood across the age span of healthy adults: A systematic review. Neuroimage Clin. 2023;40:103503. doi: 10.1016/j.nicl.2023.103503.

28. Lin, C.-H.; Lane, H.-Y. Plasma Glutathione Levels Decreased with Cognitive Decline among People with Mild Cognitive Impairment (MCI): A Two-Year Prospective Study. Antioxidants 2021, 10, 1839. https://doi.org/10.3390/antiox10111839

29. Laura M Pérez, Babak Hooshmand, Francesca Mangialasche, Patrizia Mecocci, A David Smith, Helga Refsum, Marco Inzitari, Laura Fratiglioni, Debora Rizzuto, Amaia Calderón-Larrañaga, Glutathione Serum Levels and Rate of Multimorbidity Development in Older Adults, The Journals of Gerontology: Series A, Volume 75, Issue 6, June 2020, Pages 1089–1094, https://doi.org/10.1093/gerona/glz101

30. Brodzka, S.; Baszyński, J.; Rektor, K.; Hołderna-Bona, K.; Stanek, E.; Kurhaluk, N.; Tkaczenko, H.; Malukiewicz, G.; Woźniak, A.; Kamiński, P. The Role of Glutathione in Age-Related Macular Degeneration (AMD). Int. J. Mol. Sci. 2024, 25, 4158. https://doi.org/10.3390/ijms25084158

31. Iskusnykh, I.Y.; Zakharova, A.A.; Pathak, D. Glutathione in Brain Disorders and Aging. Molecules 2022, 27, 324. https://doi.org/10.3390/molecules27010324

32. Hajjar, I., Hayek, S.S., Goldstein, F.C. et al. Oxidative stress predicts cognitive decline with aging in healthy adults: an observational study. J Neuroinflammation 15, 17 (2018). https://doi.org/10.1186/s12974-017-1026-z

33. Hu X, Pan K, Zhao M, Lv J, Wang J, Zhang X, Liu Y, Song Y, Gudmundson AT, Edden RAE, Ren F, Zhang T, Gao F. Brain extended and closed forms glutathione levels decrease with age and extended glutathione is associated with visuospatial memory. Neuroimage. 2024 Jun;293:120632. doi: 10.1016/j.neuroimage.2024.120632.

34. Diaz-Del Cerro, E.; Martinez de Toda, I.; Félix, J.; Baca, A.; De la Fuente, M. Components of the Glutathione Cycle as Markers of Biological Age: An Approach to Clinical Application in Aging. Antioxidants 2023, 12, 1529. https://doi.org/10.3390/antiox12081529

35. Wróblewska J, Wróblewski M, Hołyńska-Iwan I, Modrzejewska M, Nuszkiewicz J, Wróblewska W, Woźniak A. The Role of Glutathione in Selected Viral Diseases. Antioxidants (Basel). 2023 Jun 22;12(7):1325. doi: 10.3390/antiox12071325.

36. Labarrere CA, Kassab GS. Glutathione deficiency in the pathogenesis of SARS-CoV-2 infection and its effects upon the host immune response in severe COVID-19 disease. Front Microbiol. 2022 Oct 6;13:979719. doi: 10.3389/fmicb.2022.979719.

37. Paoletti A, Pencharz PB, Rafii M, Tomlinson C, Kong D, Xu L, Elango R, Courtney-Martin G. Protein intake affects erythrocyte glutathione synthesis in healthy adults aged ≥60 years in a repeated-measures trial. Am J Clin Nutr. 2024 Apr;119(4):917-926. doi: 10.1016/j.ajcnut.2024.02.002.

38. Sinha R, Sinha I, Calcagnotto A, Trushin N, Haley JS, Schell TD, Richie JP Jr. Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function. Eur J Clin Nutr. 2018 Jan;72(1):105-111. doi: 10.1038/ejcn.2017.132.

39. To K, Cao R, Yegiazaryan A, Owens J, Nguyen T, Sasaninia K, Vaughn C, Singh M, Truong E, Medina A, Avitia E, Villegas J, Pham C, Sathananthan A, Venketaraman V. Effects of Oral Liposomal Glutathione in Altering the Immune Responses Against Mycobacterium tuberculosis and the Mycobacterium bovis BCG Strain in Individuals With Type 2 Diabetes. Front Cell Infect Microbiol. 2021 Jun 3;11:657775. doi: 10.3389/fcimb.2021.657775. 

40. Tielan Wei, Sachin Sunil Thakur and Mengyang Liu et al. Oral delivery of glutathione: antioxidant function, barriers and strategies. Acta Materia Medica. 2022. Vol. 1(2):177-192. DOI: 10.15212/AMM-2022-0005

41. Alvaro Garcia, Nasma D. Eljack, Marc-Antoine Sani, Frances Separovic, Helge H. Rasmussen, Wojciech Kopec, Himanshu Khandelia, Flemming Cornelius, Ronald J. Clarke,

Membrane accessibility of glutathione, Biochimica et Biophysica Acta (BBA) – Biomembranes, Volume 1848, Issue 10, Part A, 2015, https://doi.org/10.1016/j.bbamem.2015.07.016.

42. Tieu, S.; Charchoglyan, A.; Paulsen, L.; Wagter-Lesperance, L.C.; Shandilya, U.K.; Bridle, B.W.; Mallard, B.A.; Karrow, N.A. N-Acetylcysteine and Its Immunomodulatory Properties in Humans and Domesticated Animals. Antioxidants 2023, 12, 1867. https://doi.org/10.3390/antiox12101867

43. Tenório, M.C.d.S.; Graciliano, N.G.; Moura, F.A.; Oliveira, A.C.M.d.; Goulart, M.O.F. N-Acetylcysteine (NAC): Impacts on Human Health. Antioxidants 2021, 10, 967. https://doi.org/10.3390/antiox10060967

44. Pedre B, Barayeu U, Ezeriņa D, Dick TP. The mechanism of action of N-acetylcysteine (NAC): The emerging role of H2S and sulfane sulfur species. Pharmacol Ther. 2021 Dec;228:107916. doi: 10.1016/j.pharmthera.2021.107916. 

45. Khalatbari Mohseni G, Hosseini SA, Majdinasab N, Cheraghian B. Effects of N-acetylcysteine on oxidative stress biomarkers, depression, and anxiety symptoms in patients with multiple sclerosis. Neuropsychopharmacol Rep. 2023 Sep;43(3):382-390. doi: 10.1002/npr2.12360.

46. Carollo, M., Carollo, N. and Montan, G. (2024), The promise of N-acetylcysteine in the treatment of obsessive-compulsive disorder. CNS Neurosci Ther, 30: e14653. https://doi.org/10.1111/cns.14653

47. Janeczek M, Moy L, Riopelle A, Vetter O, Reserva J, Tung R, Swan J. The Potential Uses of N-acetylcysteine in Dermatology: A Review. J Clin Aesthet Dermatol. 2019 May;12(5):20-26.

48. Adil M, Amin SS, Mohtashim M. N-acetylcysteine in dermatology. Indian J Dermatol Venereol Leprol 2018;84:652-659

49. Boo, Y.C. Metabolic Basis and Clinical Evidence for Skin Lightening Effects of Thiol Compounds. Antioxidants 2022, 11, 503. https://doi.org/10.3390/antiox11030503

50. Pozzo LD, Xu Z, Lin S, Wang J, Wang Y, Enechojo OS, Abankwah JK, Peng Y, Chu X, Zhou H, Bian Y. Role of epigenetics in the regulation of skin aging and geroprotective intervention: A new sight. Biomed Pharmacother. 2024 May;174:116592. doi: 10.1016/j.biopha.2024.116592.

51. Sohouli MH, Eslamian G, Malekpour Alamdari N, Abbasi M, Fazeli Taherian S, Behtaj D, Zand H. Effects of N-acetylcysteine on aging cell and obesity complications in obese adults: a randomized, double-blind clinical trial. Front Nutr. 2023 Sep 19;10:1237869. doi: 10.3389/fnut.2023.1237869.

52. Li X, Zou J, Lin A, Chi J, Hao H, Chen H, Liu Z. Oxidative Stress, Endothelial Dysfunction, and N-Acetylcysteine in Type 2 Diabetes Mellitus. Antioxid Redox Signal. 2024 Apr 29. doi: 10.1089/ars.2023.0524.

53. Cui, Y.; Zhu, Q.; Hao, H.; Flaker, G.C.; Liu, Z. N-Acetylcysteine and Atherosclerosis: Promises and Challenges. Antioxidants 2023, 12, 2073. https://doi.org/10.3390/antiox12122073

54. Sonja K. Soo, Paige D. Rudich, Annika Traa, Namasthée Harris-Gauthier, Hazel J. Shields, Jeremy M. Van Raamsdonk, Compounds that extend longevity are protective in neurodegenerative diseases and provide a novel treatment strategy for these devastating disorders, Mechanisms of Ageing and Development, Volume 190, 2020, https://doi.org/10.1016/j.mad.2020.111297.

55. Toshikawa, H., Ikenaka, A., Li, L. et al. N-Acetylcysteine prevents amyloid-β secretion in neurons derived from human pluripotent stem cells with trisomy 21. Sci Rep 11, 17377 (2021). https://doi.org/10.1038/s41598-021-96697-7

56. Kaya ZB, Karakoc E, McLean PJ, Saka E, Atilla P. Post-inflammatory administration of N-acetylcysteine reduces inflammation and alters receptor levels in a cellular model of Parkinson’s disease. FASEB BioAdvances. 2023; 5: 263-276. doi:10.1096/fba.2022-00145

57. Lizzo G, Migliavacca E, Lamers D, Frézal A, Corthesy J, Vinyes-Parès G, Bosco N, Karagounis LG, Hövelmann U, Heise T, von Eynatten M, Gut P. A Randomized Controlled Clinical Trial in Healthy Older Adults to Determine Efficacy of Glycine and N-Acetylcysteine Supplementation on Glutathione Redox Status and Oxidative Damage. Front Aging. 2022 Mar 7;3:852569. doi: 10.3389/fragi.2022.852569.

58. Kumar P, Liu C, Hsu JW, Chacko S, Minard C, Jahoor F, Sekhar RV. Glycine and N-acetylcysteine (GlyNAC) supplementation in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength, and cognition: Results of a pilot clinical trial. Clin Transl Med. 2021 Mar;11(3):e372. doi: 10.1002/ctm2.372.

59. Premranjan Kumar, Chun Liu, James Suliburk, Jean W Hsu, Raja Muthupillai, Farook Jahoor, Charles G Minard, George E Taffet, Rajagopal V Sekhar, Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial, The Journals of Gerontology: Series A, Volume 78, Issue 1, January 2023, Pages 75–89, https://doi.org/10.1093/gerona/glac135 

60. Lapenna D. Glutathione and glutathione-dependent enzymes: From biochemistry to gerontology and successful aging. Ageing Res Rev. 2023 Dec;92:102066. doi: 10.1016/j.arr.2023.102066.

61. Inal O, Amasya G, Sezgin Bayindir Z, Yuksel N. Development and quality assessment of glutathione tripeptide loaded niosome containing carbopol emulgels as nanocosmeceutical formulations. Int J Biol Macromol. 2023 Jun 30;241:124651. doi: 10.1016/j.ijbiomac.2023.124651.

62. Liu M, Sharma M, Lu GL, Zhang Z, Yin N, Wen J. Full factorial design, physicochemical characterization, ex vivo investigation, and biological assessment of glutathione-loaded solid lipid nanoparticles for topical application. Int J Pharm. 2023 Jan 5;630:122381. doi: 10.1016/j.ijpharm.2022.122381.

63. Cui X, Mi T, Xiao X, Zhang H, Dong Y, Huang N, Gao P, Lee J, Guelakis M, Gu X. Topical glutathione amino acid precursors protect skin against environmental and oxidative stress. J Eur Acad Dermatol Venereol. 2024 Jan;38 Suppl 3:3-11. doi: 10.1111/jdv.19717.

64. Wahab S, Anwar AI, Zainuddin AN, Hutabarat EN, Anwar AA, Kurniadi I. Combination of topical and oral glutathione as a skin-whitening agent: a double-blind randomized controlled clinical trial. Int J Dermatol. 2021 Aug;60(8):1013-1018. doi: 10.1111/ijd.15573.

65. Sitohang IBS, Ninditya S. Systemic Glutathione as a Skin-Whitening Agent in Adult. Dermatol Res Pract. 2020 Apr 24;2020:8547960. doi: 10.1155/2020/8547960.

66. Davids LM, Van Wyk JC, Khumalo NP. Intravenous glutathione for skin lightening: Inadequate safety data. S Afr Med J. 2016 Jul 6;106(8):782-6. doi: 10.7196/SAMJ.2016.v106i8.10878.

67. WebMD March 23, 2024 https://www.webmd.com/vitamins-and-supplements/glutathione-uses-risks

68. Healthwire Jan 11, 2024 https://healthwire.pk/healthcare/9-potential-side-effects-of-skin-whitening-injections/

69. Republic of the Philippines Philippines News February 24, 2024 https://www.pna.gov.ph/articles/1219501

70. Unsafe use of glutathione as skin lightening agent. Food and Drug Administration Philippines.July 5, 2019. Accessed January 7, 2022.https://www.fda.gov.ph/wp-content/uploads/2019/07/FDA-Advisory-No.2019-182.pdf 

71. Sonthalia S, Daulatabad D, Sarkar R. Glutathione as a skin whitening agent: Facts, myths, evidence and controversies. Indian J Dermatol Venereol Leprol 2016;82:262-72.

72. Sonthalia S, Jha AK, Lallas A, Jain G, Jakhar D. Glutathione for skin lightening: a regnant myth or evidence-based verity? Dermatol Pract Concept. 2018 Jan 31;8(1):15-21. doi: 10.5826/dpc.0801a04.

73. Sonthalia S, Daulatabad D, Sarkar R. Glutathione as a skin whitening agent: Facts, myths, evidence and controversies. Indian J Dermatol Venereol Leprol. 2016 May-Jun;82(3):262-72. doi: 10.4103/0378-6323.179088. 

74.  Park J, Shin DW. Senotherapeutics and Their Molecular Mechanism for Improving Aging. Biomol Ther (Seoul). 2022 Nov 1;30(6):490-500. doi: 10.4062/biomolther.2022.114.